ERBB2 and breast cancer: LG268, but not bexarotene, lowered infiltration of MDSCs and CD206+ macrophages, resulting in a rise in PDL1 positivity and CD8+ vs. CD4+CD25+ T-cell ratios and cytotoxicity against Her2+MMTV-Neu and triple-negative MMTV-PyM-driven breast cancer.